05.10.12
NSF-DBA, an NSF International Health Sciences Co., has signed a collaborative agreement with Semler Research Center (SRC) of Bangalore to expand pharmaceutical training, auditing, consulting and testing services throughout India. NSF-DBA’s partnership with SRC provides global and India-based pharmaceutical companies with local access to training, consulting, auditing and testing services.
SRC, the Indian subsidiary of U.S.-based Arnold A Semler, Inc., specializes in all aspects of pharmaceutical development, clinical services, bioavailability/bioequivalence testing and GxP2 auditing and consulting. The two companies will work together to harmonize consulting and auditing practices and standards, as well as train SRC staff to deliver NSF-DBA training courses.
NSF-DBA services in India now include: GxP consultancy services, clinical services, bioanalytical services, and formulation, process and analytical development. SRC’s Bangalore facility has pilot scale manufacturing equipment to develop formulations and processes for a range of dosage forms, from oral solids, through semi-solids, to liquid injectables.
“We asked for recommendations from trusted clients and professionals in the region and one name came up time after time – SRC in Bangalore,” said Bob Pietrowski, NSF-DBA managing partner. “This agreement with SRC allows NSF-DBA to better assist companies in Europe and North America who are seeking audits of suppliers and contractors in the region as part of their supply chain assurance program.”
“This collaboration with NSF-DBA brings a host of high quality and competitively priced pharmaceutical services to companies based in India. The consultants of SRC, trained by the reputed Senior Consultants of NSF-DBA, provide a wide range of services that help ensure the safety of pharmaceuticals,” said Gurudatta G.G., chief quality officer, SRC.
SRC, the Indian subsidiary of U.S.-based Arnold A Semler, Inc., specializes in all aspects of pharmaceutical development, clinical services, bioavailability/bioequivalence testing and GxP2 auditing and consulting. The two companies will work together to harmonize consulting and auditing practices and standards, as well as train SRC staff to deliver NSF-DBA training courses.
NSF-DBA services in India now include: GxP consultancy services, clinical services, bioanalytical services, and formulation, process and analytical development. SRC’s Bangalore facility has pilot scale manufacturing equipment to develop formulations and processes for a range of dosage forms, from oral solids, through semi-solids, to liquid injectables.
“We asked for recommendations from trusted clients and professionals in the region and one name came up time after time – SRC in Bangalore,” said Bob Pietrowski, NSF-DBA managing partner. “This agreement with SRC allows NSF-DBA to better assist companies in Europe and North America who are seeking audits of suppliers and contractors in the region as part of their supply chain assurance program.”
“This collaboration with NSF-DBA brings a host of high quality and competitively priced pharmaceutical services to companies based in India. The consultants of SRC, trained by the reputed Senior Consultants of NSF-DBA, provide a wide range of services that help ensure the safety of pharmaceuticals,” said Gurudatta G.G., chief quality officer, SRC.